28.61

1.44% 0.3961

Roivant Sciences Ltd (ROIV)

Overview News Price History Option Chain Financials Why ROIV Down? Discussions Forecast

Roivant Sciences Ltd stock is traded at $28.61, with a volume of 674.93K. It is up +1.44% in the last 24 hours and up +1.98% over the past month. Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Previous Close:

$28.21

Open:

$28.21

24h Volume:

674.93K

Relative Volume:

0.11

Market Cap:

$20.46B

Revenue:

$13.31M

Net Income/Loss:

$-1.01B

P/E Ratio:

-24.48

EPS:

-1.1685

Net Cash Flow:

$-766.86M

1W Performance:

+2.64%

1M Performance:

+1.98%

6M Performance:

+76.53%

1Y Performance:

+190.21%

1-Day Range:

$28.21

$29.19

1-Week Range:

$27.40

$29.19

52-Week Range:

$9.87

$30.33

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name

Roivant Sciences Ltd

Sector

Healthcare (1111)

Industry

Biotechnology (623)

Phone

441-295-5950

Address

7TH FLOOR, 50 BROADWAY, LONDON

Employee

750

Twitter

Next Earnings Date

2025-02-10

Latest SEC Filings

ROIV's Discussions on Twitter

Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ROIV Roivant Sciences Ltd	28.59	20.19B	13.31M	-1.01B	-766.86M	-1.1685
VRTX Vertex Pharmaceuticals Inc	437.09	110.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	742.06	79.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	793.45	49.73B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	326.08	42.98B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	306.28	34.37B	5.36B	287.73M	924.18M	2.5229

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-20-26	Initiated	Bernstein	Outperform
Sep-02-25	Initiated	Citigroup	Buy
Jul-10-25	Resumed	Goldman	Buy
Feb-15-24	Initiated	Wolfe Research	Outperform
Jan-05-24	Initiated	Piper Sandler	Overweight
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-17-23	Initiated	Guggenheim	Buy
Jun-08-23	Initiated	BofA Securities	Neutral
Oct-27-22	Initiated	JP Morgan	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight
Dec-15-21	Initiated	Goldman	Buy
Nov-08-21	Initiated	H.C. Wainwright	Buy
Oct-28-21	Initiated	Citigroup	Buy
Oct-26-21	Initiated	Cowen	Outperform
Oct-26-21	Initiated	Jefferies	Buy
Oct-26-21	Initiated	Truist	Buy

View All

Roivant Sciences Ltd Stock (ROIV) Latest News

01:20 AM

A Look At Roivant Sciences (ROIV) Valuation As Analyst Upgrades And Brepocitinib Progress Lift Sentiment - simplywall.st

01:20 AM

Apr 12, 2026

Montes Archimedes Acquisition (ROIV) upgraded to buy: Here's what you should know - MSN

Apr 12, 2026

(ROIV) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Apr 12, 2026

Apr 11, 2026

Roivant Sciences: How Its Unique Deal Structure With Pfizer Could Shape Long-Term Value! - Smartkarma

Apr 11, 2026

Is Brepocitinib’s LPP Trial And Mixed Batoclimab Data Altering The Investment Case For Roivant Sciences (ROIV)? - simplywall.st

Apr 11, 2026

Apr 10, 2026

Insider Sell Alert: Jennifer Humes Sells Shares of Roivant Scien - GuruFocus

Apr 10, 2026

Montes Archimedes Acquisition (ROIV) Raised to Buy: Key Information You Need - Bitget

Apr 10, 2026

Apr 09, 2026

Analysts Are Bullish on Top Healthcare Stocks: Roivant Sciences (ROIV), Boston Scientific (BSX) - The Globe and Mail

Apr 09, 2026

Apr 06, 2026